HER2 is a tyrosine kinase receptor that is part of the ErbB family of receptors. HER2 binds an extracellular ligand and activates several intracellular pathways that contribute to cell proliferation, apoptosis, adhesion, migration, and differentiation.1
HER2 is overexpressed in several cancers, including 20%-25% of breast cancers and 10%-25% of gastric cancers.1,2 Amplification of HER2 correlates with a worse prognosis and shorter overall survival in both of these malignancies.1
Numerous studies have shown that blocking HER2 inhibits downstream signaling and leads to internalization and degradation of the receptor.1
Learn more about modalities targeting HER2:
Search our clinical trials.
Download additional information from our resources section.
HER2: human epidermal growth factor receptor 2.
1. Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol. 2013;5(2):143-151. 2. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92-98.